How Do Patients Decide Where to Seek Cancer Treatment?
_kmq.push(["trackClickOnOutboundLink","wpa2a_28","Article link clicked",{"Title":"","Page":"How Do Patients Decide Where to Seek Cancer Treatment?"}]);Cancer is both a terrible, terrifying disease and...
View ArticleImmunotherapy Opdivo (Nivolumab) Approved for Chemo-Pretreated Advanced...
_kmq.push(["trackClickOnOutboundLink","wpa2a_24","Article link clicked",{"Title":"","Page":"Immunotherapy Opdivo (Nivolumab) Approved for Chemo-Pretreated Advanced Squamous NSCLC"}]);It was a big day...
View ArticleImmunotherapy Opdivo (Nivolumab) Non-Squamous NSCLC Trial Stopped, Reported...
_kmq.push(["trackClickOnOutboundLink","wpa2a_20","Article link clicked",{"Title":"","Page":"Immunotherapy Opdivo (Nivolumab) Non-Squamous NSCLC Trial Stopped, Reported as Positive"}]);In January, 2015,...
View ArticleThe Immunotherapy Cola Wars
_kmq.push(["trackClickOnOutboundLink","wpa2a_16","Article link clicked",{"Title":"","Page":"The Immunotherapy Cola Wars"}]);It’s been a big week for immunotherapy for lung cancer. Right on the heels of...
View ArticlePFS vs. pfs: Why Progression-Free Survival Remains Controversial in Lung Cancer
_kmq.push(["trackClickOnOutboundLink","wpa2a_12","Article link clicked",{"Title":"","Page":"PFS vs. pfs: Why Progression-Free Survival Remains Controversial in Lung Cancer"}]);Last year, an article...
View ArticleRattling the SABR: Provocative but Limited Data Supporting a Non-Surgical...
_kmq.push(["trackClickOnOutboundLink","wpa2a_8","Article link clicked",{"Title":"","Page":"Rattling the SABR: Provocative but Limited Data Supporting a Non-Surgical Approach to Early Stage...
View ArticleThe Many Faces of Stage III NSCLC: Why We Have Such Trouble Nailing Down an...
_kmq.push(["trackClickOnOutboundLink","wpa2a_4","Article link clicked",{"Title":"","Page":"The Many Faces of Stage III NSCLC: Why We Have Such Trouble Nailing Down an Optimal Treatment for Locally...
View ArticlePD-L1 Expression for Immunotherapy Agents in Lung Cancer? Vital or “Don’t...
In the span of a week, we’ve just had new FDA approvals of Keytruda (pembrolizumab) for previously treated advanced non-small cell lung cancer (NSCLC) patients with tumors that express PD-L1, followed...
View ArticleEvolving Thoughts on the Value of PD-L1 Testing for Second Line Non-Squamous...
After having had further discussions with colleagues about the data and the challenges in interpreting the optimal treatment in this setting, I am inclined to soften my view that Taxotere is quite...
View ArticleDirect Comparison of 2 EGFR Inhibitors Shows There Are Clinically Significant...
Fast forward 1.5 years, and we now have the early results of LUX-Lung-7, and they show that these EGFR TKIs are not completely interchangeable...Related Posts:Are There Clinically Significant...
View ArticleSurvey on Decision-Making in Lung Cancer Patients: Can You Help?
Are there things that physicians and patients can do to make the decision making process easier for lung cancer patients in some way? The survey takes approximately 15 minutes or less to...
View ArticleDivergent Paths for Tagrisso (Osimertinib) and Rociletinib for EGFR...
For patients with an activating EGFR mutation and who develop “acquired resistance”, the pattern of progression that occurs after a sometimes long period of good initial response to an oral EGFR...
View ArticleCan “Local” Therapy in Metastatic Lung Cancer Alter the Path for Systemic...
After completing my unpacking from ASCO and beginning to see a path of light as I dig out from under the backup of work that accumulated, I wanted to begin covering a few of the most relevant content...
View ArticleKeytruda (Pembrolizumab) Beats Chemo as First Line Therapy for Patients with...
It seemed inevitable, I think. Several immuntherapy agents known as PD-1 or PD-L1 checkpoint inhibitors have been shown to lead to better survival, higher response rates, and a better side effect...
View ArticleShould Alecensa (Alectinib) be the new first line ALK inhibitor for...
Probably the most immediate potentially practice-changing presentation from ASCO was the Japanese J-ALEX study in the subset of about 4-5% of patients with non-small cell lung cancer (NSCLC) who have...
View ArticleCheckMate 026 trial fails to show benefit for Opdivo (nivolumab) in first...
The transition of PD1 and PD-L1 inhibitors into the first line setting for at least some patients with advanced non-small cell lung cancer (NSCLC) is poised to be the biggest sea change in the...
View ArticleIt’s most likely the study population, not the drug choice, that leads to...
Yesterday, news that the Checkmate 026 trial that compared the PD1 checkpoint inhibitor Opdivo (nivolumab) to standard chemotherapy as first line treatment for advanced non-small cell lung cancer...
View ArticleOAK trial with Tecentriq (atezolizumab) is positive: How a “me too” result...
With positive trials of two immune checkpoint inhibitors, Opdivo (nivolumab) and Keytruda (pembrolizumab), in second line NSCLC and compared with Taxotere (docetaxel), it should come as a surprise to...
View ArticleDeath by “Pseudo-progression”: Knowing When to Cut Your Losses with...
Among the many novel concepts in managing immunotherapy is the potential for “pseudo-progression”. This unusual phenomenon is when a patient’s scans of the areas of cancer actually appear worse on...
View ArticleIs immunotherapy the wrong choice for some lung cancer patients?
Amidst all of the glowing reports about immunotherapy for lung and many other cancers, it would be understandable for patients and physicians to be tempted to rush toward prioritizing immunotherapy as...
View ArticleFirst Line Immunotherapy for Advanced Non-Small Cell Lung Cancer: A Great...
Several weeks ago, at a very crowded plenary session for the European Society of Medical Oncology (ESMO) in Copenhagen, Denmark, results with first line immunotherapy compared to standard first line...
View ArticleImprecision Medicine: Why Keytruda (Pembrolizumab) + Chemo for PD-L1+ NSCLC...
Let me start by saying that I’m a fan of the immune checkpoint inhibitor Keytruda (pembrolizumab) and consider it the new standard of care as a single agent (monotherapy) first line treatment for the...
View ArticleNew FDA Approval for Zykadia (ceritinib) for ALK-Positive NSCLC: Why I Think...
The FDA just approved a new therapy for the approximately 4% of patients with NSCLC who have the molecular marker known as an ALK rearrangement. The agent Zykadia (ceritinib), a “second generation” ALK...
View ArticleMy Top 10 ASCO 2017 Lung Cancer Presentations
Over the next few days, about 30,000 oncologists and other cancer care professionals, along with a growing number of patient advocates, are converging on Chicago for the American Society for Clinical...
View ArticleWhy I Don’t Favor an Front-Loaded Approach for Most Advanced NSCLC Patients
To many, the recent FDA approval of a combination of chemotherapy and concurrent immunotherapy for the vast majority of patients with advanced (metastatic) non-squamous non-small cell lung cancer...
View Article
More Pages to Explore .....